Healthy
Conditions
Brief summary
This is a Phase 1, randomized, 2 way crossover, multiple dose, open label study of the effect of PF 04965842 on rosuvastatin PK in healthy participants. Participants will be randomized to 1 of the 2 treatment sequences. A total of approximately 12 healthy male and/or female participants will be enrolled in the study so that approximately 6 participants will be enrolled in each treatment sequence. Each treatment sequence will consist of 2 periods. In both sequences, participants will remain in the CRU for a total of 11 days and 10 nights (including Period 1 and Period 2). To adequately remove any drug effects of rosuvastatin from Period 1 to Period 2, there will be a minimum 5 day washout period between the 2 rosuvastatin dosing events.
Interventions
DRUGPF-04965842
200 mg dose of PF-04965842 once daily (QD) for 3 days
DRUGRosuvastatin
Single 10 mg dose of rosuvastatin
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Participants are eligible to be included in the study only if all of the following criteria apply: Age and Sex: 1. Male and female participants must be 18 to 55 years of age, inclusive, at the time of signing the informed consent document (ICD). Type of Participant and Disease Characteristics: 2. Male and female participants who are overtly healthy as determined by medical evaluation including a detailed medical history, complete physical examination, laboratory tests, and ECG. 3. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. Weight: 4. Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb). Informed Consent: 5. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol.
Exclusion criteria
Participants are excluded from the study if any of the following criteria apply: Medical Conditions: 1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic (including alcoholic liver disease, nonalcoholic steatohepatitis (NASH), autoimmune hepatitis, and hereditary liver diseases), psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). 2. Evidence of acute exacerbation or history of clinically significant dermatological condition (eg, contact dermatitis or psoriasis) or visible rash present during physical examination. 3. Participants, who according to the product label for rosuvastatin, would be at increased risk if dosed with rosuvastatin. 4. Self reported history or risk factors for QT prolongation or torsades de pointes (eg, organic heart disease, congestive heart failure, hypokalemia, hypomagnesaemia, congenital long QT syndrome, myocardial ischemia or infarction), congenital deafness, family history of sudden death, and family history of long QT syndrome. 5. Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy, appendectomy). 6. A current or past medical history of conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction. 7. History of human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus infection; positive testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), or hepatitis C antibody (HCVAb). As an exception, a positive hepatitis B surface antibody (HepBsAb) as a result of participant vaccination is permissible. 8. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study. Prior/Concomitant Therapy: 10\. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of investigational product. 10\. Use of CYP2C19 inhibitors (eg, fluconazole, fluoxetine, fluvoxamine, ticlopidine omeprazole, voriconazole, cimetidine, esomeprazole, and felbamate) or inducers (eg, rifampin, ritonavir, efavirenz, enzalutamide, phenytoin, and St. John's Wort) within 28 days or 5 half-lives (whichever is longer) prior to dosing. 11\. Use of CYP2C9 inhibitors (eg, amiodarone, felbamate, fluconazole, miconazole, piperine, diosmin, disulfiram, fluvastatin, fluvoxamine, voriconazole, efavirenz, isoniazid) or inducers (eg, aprepitant, carbamazepine, enzalutamide, rifampin, ritonavir, nevirapine, phenobarbital, and St. John's Wort) within 28 days or 5 half lives (whichever is longer) prior to dosing. 12\. Use of CYP3A4 inhibitors (eg, ketoconazole, ciprofloxacin, diltiazem) or other inducers (eg, phenytoin, carbamazepine) within 28 days or 5 half-lives (whichever is longer) prior to dosing. Prior/Concurrent Clinical Study Experience: 13\. Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of investigational product used in this study (whichever is longer). Diagnostic Assessments: 14\. A positive urine drug test. 15. Screening supine systolic blood pressure (BP) \<90 mm Hg or \>=140 mm Hg following at least 5 minutes of supine rest; OR Screening supine diastolic BP \<50 mm Hg or \>=90 mm Hg following at least 5 minutes of supine rest. If a participant meets any of these criteria, the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility. 16\. Screening supine 12 lead ECG demonstrating: * QTcF \>450 msec; OR * QRS interval \>120 msec. If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine the participant's eligibility. 17\. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary: * Alkaline phosphatase, creatine kinase, aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) or alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) level \> ULN. * Total bilirubin level \> ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is \<=ULN. * Estimated creatinine clearance \<90 mL/min. * Confirmed microscopic proteinuria or hematuria. Other Exclusions: 18\. History of regular alcohol consumption exceeding 14 drinks per week for female participants or 21 drinks per week for male participants (1 drink = 5 ounces \[150 mL\] of wine or 12 ounces \[360 mL\] of beer or 1.5 ounces \[45 mL\] of hard liquor) within 6 months before screening. 19\. Known relevant history of elevated liver function tests (LFTs). 20. History of tuberculosis (TB) (active or latent) or inadequately treated TB infection. Positive QuantiFERON - TB Gold test. 21\. Any history of chronic infections, any history of recurrent infections, any history of latent infections, or any acute infection within 2 weeks of baseline. 22\. History of disseminated herpes zoster, or disseminated herpes simplex, or recurrent localized dermatomal herpes zoster. 23\. History of systemic infection requiring hospitalization, parenteral antimicrobial therapy, or considered clinically significant by the investigator within 6 months prior to screening. 24\. History of receiving a live vaccine within 6 weeks prior to the first dose of investigational product, or is expected to receive a live vaccine within 6 weeks after the last dose of investigational product. 25\. Have a known immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency. 26\. History of sensitivity to heparin or heparin induced thrombocytopenia. 27. Use of tobacco or nicotine containing products in excess of the equivalent of 5 cigarettes per day. 28\. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to first dose of investigational product. 29\. History of hypersensitivity to rosuvastatin. 30. Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol. 31\. Have any malignancies or have a history of malignancies with the exception of adequately treated or excised non metastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ. 32\. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUCinf of rosuvastatin. | 72 hrs after rosuvastatin administration in Period 1 and 2 | Area under the curve from time zero to extrapolated infinite time for rosuvastatin |
| CLr of rosuvastatin | 72 hrs after rosuvastatin administration in Period 1 and 2 | Renal clearance for rosuvastatin |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cmax of rosuvastatin | 72 hours after rosuvastatin administration in Period 1 and 2 | Maximum observed plasma concentration for rosuvastatin |
| t1/2 of rosuvastatin | 72 hours after rosuvastatin administration in Period 1 and 2 | apparent terminal half life of rosuvastatin |
| Ae of rosuvastatin | 72 hours after rosuvastatin administration in Period 1 and 2 | Amount of rosuvastatin excreted in urine |
| AUClast of rosuvastatin | 72 hours after rosuvastatin administration in Period 1 and 2 | Area under the plasma concentration time curve from 0 to the time of last measurement of rosuvastatin |
| Number of subjects with adverse events (AEs). | Screening up to 28-35 days after the last dose of PF 04965842 in period 2 | Number of subjects with adverse events (AEs) |
| Number of subjects with laboratory tests findings of potential clinical importance | Screening through Day 5 of period 2 | Number of subjects with laboratory tests findings of potential clinical importance |
| Number of subjects with clinically significant abnormal vital signs | Screening through Day 5 of period 2 | Number of subjects with clinically significant abnormal vital signs |
| Ae% of rosuvastatin | 72 hours after rosuvastatin administration in Period 1 and 2 | Percent of dose of rosuvastatin excreted in urine |
| Tmax of rosuvastatin | 72 hours after rosuvastatin administration in Period 1 and 2 | Time to maximum concentration of rosuvastatin |
Countries
Belgium
Outcome results
None listed